Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2015 | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | LANCET ONCOLOGY |